

# Expanding business and trade with CIS Region — Healthcare {Taj Pharmaceuticals}

*Abhishek Singh CEO Taj Pharmaceuticals India states that; there is a general awareness about the, CIS Region (Commonwealth of Independent States)*

MUMBAI, MAHARASHTRA, INDIA, June 12, 2020 /EINPresswire.com/ -- India's major healthcare exports to CIS countries includes Pharmaceutical products, Electrical machinery and equipment and parts thereof, Machinery, Mechanical appliances, Organic chemicals; Coffee, tea, spices, Vehicles other than railway or tramway rolling stock, and parts and accessories thereof, Iron and steel etc.

[Abhishek Singh CEO Taj Pharmaceuticals India](#) states that; there is a general awareness about the, CIS Region (Commonwealth of Independent States) consists of 12 countries namely Kazakhstan, Turkmenistan, Uzbekistan, Kyrgyzstan, Tajikistan, Russian Federation, Georgia, Azerbaijan, Armenia, Ukraine, Belarus and Moldova.

It is observed that in spite of large market size and great potential, India's exports to the CIS region was USD 5.3 Billion in 2019, and constituted only 1.2% in overall CIS imports. In order to enhance India's share and volume in CIS imports, Department of Commerce has requested to



Taj Pharmaceuticals India



Taj Pharma Manufacturing

identify the issues/reasons for low penetration and measures required to be taken to increase our trade.

In case you have any inputs/suggestions in this regard, kindly send us the same(Country wise) latest by June 20th, 2020 at info ( @ ) tajpharma dot com to enable us to forward the same to the Indian Ministry's so that the same can be taken up with the respective authorities dot



Taj Pharma India

About Taj Pharma Russia and CIS operations (ТАДЖ ФАРМА)

[TAJ PHARMA CIS](#) (ТАДЖ ФАРМА) is Russia's leading innovative Generics and branded Pharmaceuticals Company; it combines a world-class research and development center, ultra-modern pharmaceutical and generics manufacturing facilities, as well as preclinical and clinical research infrastructure compliant with international standards to develop first generics.

“

Taj Pharmaceutical an Industrial conglomerate, having diversified interest in Pharmaceuticals and healthcare, Chemicals, API and Agro commodities mainly offers unique opportunities.”

*Abhishek Kumar Singh*

TAJ PHARMA CIS (ТАДЖ ФАРМА) is one of the world`s few full-cycle generic drug development and manufacturing companies, from new molecule discovery and first bio-similar's to large-scale commercial production and marketing support.

TAJ PHARMA CIS (ТАДЖ ФАРМА)`s medicines are dedicated to treat complex health conditions such as renal insufficiency, Cancer, Hepatitis C and HIV infections and

other disorders.

Taj Pharma CIS offers a range of “comprehensive” product registration, marketing authorization, in-licensing and out-licensing of pharmaceuticals products; and holds expertise to register pharmaceuticals products from formulation design up to international products registration and distribution. We specialize in the marketing, distribution, product registration of an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids, Pre-filled syringes and high-potency products.

We hold top positions in established Moscow and Turkmenistan, Baku, Azerbaijan, Kazakhstan

etc; with our unique products and are building a strong presence in many CIS markets.

Mr.Shantanu Kumar Singh  
TAJ PHARMACEUTICALS LIMITED  
+91 84484 44095

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/519281316>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.